Sign in Sign up for free

0TDD
Novo Nordisk A/S
Compare

Market cap $305.33B
Enterprise value N/A
Revenue kr167.195B
EBITDA kr72.022B
Income kr52.825B
Revenue Q/Q 27.92%
Revenue Y/Y 24.21%
P/E 42.04
Forward P/E N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 13.34
P/FCF 5.13
Price/Book 25.96
Book/Share 5.41
Cash/Share 1.34
FCF yield 2.67%
Employees 46,982
RPE kr3.559M
Volume 148.000 / 19.345k
Relative vol. 0.01 ×
EPS 3.34
EPS Q/Q N/A
Est. EPS Q/Q N/A
Profit margin 33.92%
Oper. margin 43.10%
Gross margin 83.20%
EBIT margin 43.10%
EBITDA margin 43.08%
Ret. on assets 24.76%
Ret. on equity 73.26%
ROIC 28.26%
ROCE 64.00%
Debt/Equity 1.75
Net debt/EBITDA -0.33
Current ratio 0.92
Quick ratio 0.74
Volatility 9.36%
Beta 0.31
RSI 59.50
Range $0.00 – $140.51
52 weeks $86.97 – $199.60
SMA 50 $135 +4.08%
SMA 200 $121 +13.87%
1 year target N/A
Mean Recomm. N/A
Insider ownership 0.00%
Inst. ownership 8.30%
Shares outst. 2.414B
Shares float 1.619B 67.05%
Short % of float N/A
Short ratio N/A
1 year target N/A
Mean Recomm. N/A
Dividend N/A
Dividend yield N/A
Payout ratio N/A
Payment date N/A
Ex-dividend date N/A
Earnings date N/A
IPO year 2020
Country Denmark
Compare with other stocks

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

N/A

All time

Sign up for free

Recent Novo Nordisk A/S news
Filter

Tuesday, 18 June 2024
 
abcnews.go
 Blaze at Danish drugmaker Novo Nordisk is the third in a little over a month
Monday, 17 June 2024
 
barrons
 New Weight-Loss Drugs and Devices Are Coming This Week
Friday, 14 June 2024
 
reuters
 Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
Wednesday, 12 June 2024
 
investors
 ASML, Novo Nordisk, Spotify Boast This Sign Of Stock Market Leadership
barrons
 Bernie Sanders Wants to Subpoena Novo Nordisk Over Wegovy’s Price. What to Know.
Wednesday, 5 June 2024
 
reuters
 Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
investors
 Netflix, Novo Nordisk Join 3 Fashionable Breakouts; 4 IPOs In Focus
Friday, 31 May 2024
 
bloomberg
 Goldman Sees Obesity-Drug Market Growing to $130 Billion by 2030
Tuesday, 28 May 2024
 
reuters
 Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Monday, 27 May 2024
 
insidermonkey
 The Biggest Biotechnology Company in Europe
Tuesday, 21 May 2024
 
reuters
 Eli Lilly's diabetes drug tirzepatide gets approval in China
Monday, 20 May 2024
 
barrons
 Hims & Hers Stock Spikes. It’s Taking on Big Pharma With Cheap Obesity Shots.
Saturday, 18 May 2024
 
investors
 Microsoft Leads Five Stocks Near Buy Points As Market Flashes Green
Wednesday, 15 May 2024
 
bloomberg
 Novo Nordisk Weigh-Loss Drugs Could Bankrupt US Health Care, Senate Committee Report Says
reuters
 No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
reuters
 Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound

Filter news

Novo Nordisk A/S executives

Insider Age Since Compensation
Lars Fruergaard Jorgensen (55) Pres, CEO, and Member of Management Board 55 $5,424,793
Henrik Ehlers Wulff (51) Exec. VP, Head of Product Supply, Quality, IT, and Member of the Management Board 51 $2,112,174
Camilla Sylvest (49) Exec. VP, Head of Commercial Strategy, Corp. Affairs, and Member of the Management Board 49 $2,005,806
Karsten Munk Knudsen (50) Exec. VP, CFO, and Member of the Management Board 50 $2,005,806
Monique Carter (48) Exec. VP, Head of People, Organisation, and Member of Management Board 48 $1,519,550
Marcus Schindler Ph.D. (55) Exec. VP of Research, Early Devel., CSO, and Member of the Management Board 55
Martin Holst Lange
Ludovic Helfgott (47) Exec. VP, Head of Biopharm, and Member of Management Board 47
Douglas J. Langa (55) Exec. VP, Head of North America Operations, and Member of Management Board 55
Maziar Mike Doustdar (51) Exec. VP, Head of International Operations, and Member of the Management Board 51

Novo Nordisk A/S novonordisk.com

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

  • Miscellaneous > n/a
  • Novo Nordisk A/S, Novo Allé 1, Bagsvaerd 2880, Denmark
  • 45 44 44 88 88
  • Investor relations

Profit margin

Debt to assets

Cash flow

Balance sheet

XSLX
XSLX
(in millions DKK) 29 Sep 2022 29 Jun 2022 30 Mar 2022 30 Dec 2021
Current assets
Cash kr28,465 kr22,758 kr13,394 kr10,720
Short term investments kr9,008 kr8,279 kr6,752 kr6,765
Net receivables kr53,510 kr46,639 kr44,166 kr46,799
Inventory kr23,222 kr21,706 kr20,289 kr19,621
Other current assets kr5,277 kr3,597 kr1,936 kr1,690
Total current assets kr119,482 kr102,979 kr86,537 kr85,595
Long term investments kr1,239 kr1,242 kr1,279 kr1,441
Property, plant & equipment kr63,641 kr59,556 kr56,399 kr55,362
Goodwill kr4,346
Intangible assets kr46,924 kr44,590 kr43,344 kr38,825
Other assets kr11,550 kr10,561 kr9,577 kr8,939
Deferred long term asset charges kr11,303 kr10,309 kr9,338 kr8,672
Total assets kr242,836 kr218,928 kr197,136 kr194,508
Current liabilities
Accounts payable kr8,310 kr14,654 kr6,679 kr8,870
Short long term debt
Other current liabilities kr120,114 kr93,745 kr87,527 kr26,395
Total current liabilities kr130,257 kr109,655 kr95,602 kr99,516
Long term debt kr24,136 kr24,178 kr24,084 kr9,654
Other liabilities kr11,763 kr10,643 kr10,900 kr11,285
Deferred long term liabilities
Minority interest
Total liabilities kr166,156 kr144,476 kr130,586 kr123,762
Stockholders' equity
Stock option warrants
Common stock kr456 kr456 kr462 kr462
Retained earnings kr73,673 kr73,166 kr66,612 kr72,004
Treasury stock kr2,551 kr830 -kr524 -kr1,720
Capital surplus
Other stockholder equity kr2,555 kr833 -kr517 -kr1,714
Total stockholder equity kr76,680 kr74,452 kr66,550 kr70,746
Net tangible assets kr29,756 kr29,862 kr23,206 kr27,575
(in millions DKK) 2021 2020 2019
Current assets
Cash kr10,720 kr12,757 kr15,475
Short term investments kr6,765
Net receivables kr46,799 kr32,184 kr29,152
Inventory kr19,621 kr18,536 kr17,641
Other current assets kr1,690 kr2,332 kr188
Total current assets kr85,595 kr65,809 kr62,456
Long term investments kr1,441 kr1,648 kr1,808
Property, plant & equipment kr55,362 kr50,269 kr50,551
Goodwill kr4,346
Intangible assets kr38,825 kr20,657 kr5,835
Other assets kr8,939 kr6,539 kr4,962
Deferred long term asset charges kr8,672 kr5,865 kr4,121
Total assets kr194,508 kr144,922 kr125,612
Current liabilities
Accounts payable kr8,870 kr5,717 kr6,358
Short long term debt
Other current liabilities kr26,395 kr57,097 kr51,151
Total current liabilities kr99,516 kr70,273 kr58,983
Long term debt kr9,654
Other liabilities kr11,285 kr8,427 kr6,027
Deferred long term liabilities
Minority interest
Total liabilities kr123,762 kr81,597 kr68,019
Stockholders' equity
Stock option warrants
Common stock kr462 kr470 kr480
Retained earnings kr72,004 kr63,774 kr57,817
Treasury stock -kr1,720 -kr919 -kr704
Capital surplus
Other stockholder equity -kr1,714 -kr911 -kr694
Total stockholder equity kr70,746 kr63,325 kr57,593
Net tangible assets kr27,575 kr42,668 kr51,758

Income statement

XSLX
XSLX
(in millions DKK) 29 Sep 2022 29 Jun 2022 30 Mar 2022 30 Dec 2021
Revenue
Total revenue kr45,566 kr41,265 kr42,031 kr38,333
Cost of revenue kr7,200 kr6,069 kr6,917 kr6,241
Gross profit kr38,366 kr35,196 kr35,114 kr32,092
Operating activities
Research & development kr5,633 kr5,123 kr5,206 kr5,059
Selling, general & administrative kr12,609 kr11,831 kr11,153 kr12,822
Non-recurring
Other operating expenses -kr60 -kr149 -kr392 -kr120
Total operating expenses kr25,382 kr22,874 kr22,884 kr24,002
Operating income kr20,184 kr18,391 kr19,147 kr14,331
Income from continuing operations
Net other income -kr2,152 -kr1,596 -kr1,228 -kr1,218
EBIT kr20,184 kr18,391 kr19,147 kr14,331
Interest expense -kr1,715
Income before tax kr18,032 kr16,795 kr17,919 kr13,113
Income tax expense kr3,627 kr3,477 kr3,709 kr2,221
Minority interest
Net income from continuing ops kr14,405 kr13,318 kr14,210 kr10,892
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
Net income kr14,405 kr13,318 kr14,210 kr10,892
Income (for common shares) kr14,405 kr13,318 kr14,210 kr10,892
(in millions DKK) 2021 2020 2019
Revenue
Total revenue kr140,800 kr126,946 kr122,021
Cost of revenue kr23,658 kr20,932 kr20,088
Gross profit kr117,142 kr106,014 kr101,933
Operating activities
Research & development kr17,199 kr15,112 kr14,220
Selling, general & administrative kr41,058 kr36,886 kr35,830
Non-recurring
Other operating expenses -kr456 -kr460 -kr600
Total operating expenses kr81,459 kr72,470 kr69,538
Operating income kr59,341 kr54,476 kr52,483
Income from continuing operations
Net other income -kr261 -kr1,346 -kr3,930
EBIT kr59,341 kr54,476 kr52,483
Interest expense -kr289 -kr390 -kr220
Income before tax kr59,080 kr53,130 kr48,553
Income tax expense kr11,323 kr10,992 kr9,602
Minority interest
Net income from continuing ops kr47,757 kr42,138 kr38,951
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
Net income kr47,757 kr42,138 kr38,951
Income (for common shares) kr47,757 kr42,138 kr38,951

Cash flows

XSLX
XSLX
(in millions DKK) 29 Sep 2022 29 Jun 2022 30 Mar 2022 30 Dec 2021
Net income kr14,405 kr13,318 kr14,210 kr10,892
Operating activities
Depreciation kr2,041 kr1,636 kr1,650 kr1,168
Net income adjustments kr18,803 kr4,918 kr5,833 -kr4,589
Change in accounts receivable -kr12,909
Changes in liabilities kr3,153
Changes in inventory -kr1,085
Changes in other operating activities -kr11,010 kr4,089 kr1,893 kr153
Total cash flows from operations kr24,239 kr23,961 kr23,586 -kr3,017
Investing activities
Capital expenditures -kr3,230 -kr2,435 -kr1,520 -kr2,049
Investments -kr736 -kr1,625 -kr127 -kr6
Other cash flows from investing
Total cash flows from investing -kr4,961 -kr4,200 -kr1,907 -kr20,603
Financing activities
Dividends paid -kr9,613 -kr15,690 -kr15,690
Sale and purchase of stock
Net borrowings -kr330 -kr244 -kr1,705 kr12,061
Other cash flows from financing -kr2,737 kr2,737 kr2,737
Total cash flows from financing -kr14,563 -kr10,431 -kr19,135 kr4,549
Effect of exchange rate kr443 kr218 -kr55 kr300
Change in cash and equivalents kr5,158 kr9,548 kr2,489 -kr18,771
(in millions DKK) 2021 2020 2019
Net income kr47,757 kr42,138 kr38,951
Operating activities
Depreciation kr5,111 kr5,069 kr4,679
Net income adjustments kr10,588 kr8,890 kr6,540
Change in accounts receivable -kr12,909 -kr2,822 -kr2,126
Changes in liabilities kr3,153 -kr641 -kr398
Changes in inventory -kr1,085 -kr895 -kr1,305
Changes in other operating activities kr2,185 kr5 kr441
Total cash flows from operations kr55,000 kr51,951 kr46,782
Investing activities
Capital expenditures -kr6,335 -kr5,825 -kr8,932
Investments -kr5,941 -kr380 -kr299
Other cash flows from investing kr4 kr18 kr20
Total cash flows from investing -kr31,605 -kr22,436 -kr11,509
Financing activities
Dividends paid -kr21,517 -kr20,121 -kr19,409
Sale and purchase of stock
Net borrowings kr15,471 kr4,732 -kr741
Other cash flows from financing
Total cash flows from financing -kr25,493 -kr32,244 -kr35,484
Effect of exchange rate kr591 -kr456 -kr7
Change in cash and equivalents -kr1,507 -kr3,185 -kr218
What symbols do you want to compare 0TDD with?
Please separate symbols by ','
Cancel